Bystolic (nebivolol) / Menarini, AbbVie - LARVOL DELTA

IDENTIFYING MEANINGFUL PATIENT SAVINGS ON GENERICS: DIRECT-TO-CONSUMER PRICES VS COMMERCIAL INSURANCE (ISPOR 2026) - "DTC pharmacies such as MCCPDC meaningfully lower out-of-pocket costs for higher-cost generic prescriptions which could otherwise be difficult to afford. Commercially insured patients should consider DTC pharmacies when their copayment or coinsurance for a generic medication exceeds $15, and particularly when it exceeds $100."

Clinical • Reimbursement • US reimbursement • CNS Disorders • Depression • Endocrine Disorders • Erectile Dysfunction • Multiple Sclerosis

Beta-Blockers for the Treatment of Arrhythmias: Which Drug for Which Arrhythmia? A State-of-the-Art Narrative Review. (PubMed, Am J Cardiovasc Drugs) - "In adrenergically mediated inherited syndromes, namely catecholaminergic polymorphic ventricular tachycardia and long QT syndrome, nonselective agents and especially nadolol are clearly superior to beta1-selective agents, and the same principle appears to extend to ventricular electrical storm, in which propranolol has outperformed metoprolol in a randomized comparison. In acute care, pharmacokinetics dominate, and the ultra-short-acting agents esmolol and landiolol permit a degree of titration that longer-acting drugs cannot match. In patients with heart failure and reduced ejection fraction, carvedilol, metoprolol succinate, and bisoprolol should be preferred irrespective of arrhythmia subtype because of their established mortality benefit. Conversely, beta1-selective agents, including the highly selective agent nebivolol, improve tolerability in bronchospastic disease, although this reflects respiratory tolerability rather than any demonstrated antiarrhythmic..."

Journal • Review • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Ventricular Tachycardia

Long-term clinical outcomes of carvedilol versus nebivolol in patients with ST-segment elevation myocardial infarction treated with second-generation drug-eluting stents: insights from a Korean nationwide multicenter prospective registry. (PubMed, Front Cardiovasc Med) - "All-cause mortality (4.4% vs. 3.4%; HR: 1.315, 95% CI: 1.102-1.569, p = 0.002) and revascularization (7.0% vs. 6.2%, p = 0.043; HR: 1.15, 95% CI: 1.00-1.32, p = 0.043) were also higher in the nebivolol group compared with carvedilol. In this contemporary cohort of patients with STEMI treated with DES, carvedilol was associated with better long-term clinical outcomes, including lower risks of MACE and all-cause mortality, compared with nebivolol."

Clinical data • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders • Myocardial Infarction • Thrombosis

Effect of nebivolol on nitric oxide availability and ADMA concentration in CAD patients after PCI: Prospective randomized double-blind study. (PubMed, Qatar Med J) - "In patients after PCI, treatment for 42 days was found to significantly enhance NO availability and decrease systemic ADMA concentration by nebivolol. These results clearly establish that nebivolol has the potential to restore vascular homeostasis in the high-risk vascular window, hence making it an ideal supplementary treatment for patients having atherosclerotic diseases."

Journal • Atherosclerosis • Cardiovascular • Coronary Artery Disease

Metabolic Disturbances Associated with Beta-Blocker Therapy: New Insights from a Large-Scale Pharmacovigilance Study. (PubMed, Pharmaceuticals (Basel)) - "Objective: We investigated the association between selected BBs and metabolic diseases using a large pharmacovigilance database and compared the reporting profiles of metoprolol (MET), carvedilol (CAR), bisoprolol (BIS), and nebivolol (NEB). MET and to a lesser extent CAR were associated with higher reporting odds of metabolic diseases, whereas BIS and especially NEB demonstrated more favorable reporting profiles. Although causality cannot be established from spontaneous reporting data, these findings support individualized BB selection and closer metabolic monitoring in patients with cardiometabolic risk factors."

Adverse events • Journal • Cardiovascular • Diabetes • Dyslipidemia • Genetic Disorders • Hypertriglyceridemia • Inflammation • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Administration of nebivolol after subcutaneous ovarian autotransplantation improves neoangiogenesis, follicular survival, and growth in mice. (PubMed, Reprod Fertil Dev) - "This study has opened new perspectives for the use of pharmacological angiogenic inducers to preserve ovarian integrity and function after transplantation."

Journal • Preclinical • Cardiovascular • Transplantation

Comparative clinical outcomes of nebivolol versus bisoprolol in patients with STEMI after primary PCI: a propensity-score matched analysis (ESC 2026) - "Among patients with STEMI treated with primary PCI, nebivolol and bisoprolol were associated with comparable clinical outcomes."

Clinical • Clinical data • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Thrombosis

Biochemical detection and psychosocial correlates of antihypertensive adherence in hypertension: initial observations from a cross-sectional study in two Irish tertiary care centres (ESC 2026) - "Amlodipine showed 96% detection (n=75), while nebivolol had the lowest detection (55%, n=11).Biochemically confirmed non-adherence was not identified by self-report and was unrelated to demographic factors...Biochemically confirmed non-adherence was not identified by self-report and was unrelated to demographic factors. Depressive symptoms and sceptical medication beliefs were associated with CAT-detected non-adherence and higher BP. To our knowledge, the association between an attitudinal belief profile and objectively measured non-adherence has not previously been described in CAT-based hypertension cohorts."

Adherence • Observational data • Cardiovascular • Hypertension

Comparative efficacy and safety of nebivolol in hypertension: a systematic review and network meta-analysis (ESC 2026) - "This comprehensive NMA establishes that nebivolol delivers significant SBP and DBP lowering compared with placebo, whilst outperforming traditional beta-blockers in overall blood pressure normalisation. Its proven efficacy in younger demographics, combined with a highly favourable impact on erectile function, reinforces nebivolol as an optimal therapeutic choice for managing hypertension across diverse patient groups."

Retrospective data • Review • Cardiovascular • Hypertension

Development of pH-Sensitive β‑Adrenergic Receptor Antagonists. (PubMed, ACS Pharmacol Transl Sci) - "Starting from FDA-approved β-blockers including bisoprolol, metoprolol, propranolol, and nebivolol, chemical synthesis, physicochemical studies, in vitro pharmacological investigations, and structure-activity relationship studies led to ligands with considerably higher potency at representative acidic pH values of 6 and 6.5 compared to a pH of 7.4, which is typical for ligand binding at the plasma membrane. Bis-fluorination in the beta position of nitrogen substituents was the most effective and led to pH-sensitive analogs of bisoprolol, metoprolol, and propranolol with 10- to 12-fold higher potencies at endosome-specific pH values. Because endosomal β-adrenergic receptors are suggested to be associated with heart hypertrophy and cardiac dysfunction, the newly developed ligands may serve as lead compounds for the development of powerful and safe cardioprotective drugs."

Journal

Effects of Propranolol, Metoprolol, and Nebivolol on isolated rat atrial preparations and thoracic aorta: Involvement of nitric oxide in nebivolol-induced negative chronotropic and inotropic responses. (PubMed, Physiol Int) - "These findings demonstrate that propranolol, metoprolol, and nebivolol show differential pharmacological profiles affecting atrial and vascular responses under NA stimulation in isolated rat atrial and aorta preparations. Notably, NO appears to be a key mediator of nebivolol's cardiac effects, reflected in its pronounced negative chronotropic and inotropic responses in isolated atrial tissues."

Journal • Preclinical • Cardiovascular

Mechanistic intersections of empagliflozin and nebivolol in aging-associated redox and inflammatory pathways. (PubMed, Front Pharmacol) - "Comparative consideration is also given to established aging-relevant candidates, including metformin, rapamycin, resveratrol, GLP-1 receptor agonists, NAD+ modulators, and senolytic strategies, in order to contextualize the potential relevance and limitations of metabolic-vascular pathway modulation in aging research. Rather than proposing definitive evidence of aging-relevant efficacy, the available literature supports a biologically plausible framework in which modulation of metabolic and vascular pathways may influence interconnected mechanisms underlying aging-related decline. Further integrative experimental and translational studies are required to determine whether coordinated targeting of these pathways may provide meaningful therapeutic benefit in aging and age-associated disorders."

Journal • Review • Cardiovascular • Inflammation • Metabolic Disorders

Efficacy and Safety of the Extemporaneous Combination Nebivolol/Amlodipine in Patients with Hypertension Uncontrolled on Monotherapy: The BOTTICELLI Study. (PubMed, High Blood Press Cardiovasc Prev) - "This study adds to the existing evidence supporting the efficacy and safety of the NEB/AML combination at two dose levels in managing hypertension and bringing patients at target goal."

Journal • Monotherapy • Acute Myelogenous Leukemia • Cardiovascular • Hypertension

A meta-analysis of randomized controlled trials on atenolol's impact on postoperative atrial fibrillation in adults undergoing cardiac surgery. (PubMed, Medicine (Baltimore)) - "Atenolol did not demonstrate superiority over sotalol in reducing POAF (RR, 2.39; 95% CI: 1.41-4.04; P = .001) with moderate heterogeneity (I2 = 40%; P = .19). Furthermore, no significant difference was observed between atenolol and the control group (comprising propafenone, metoprolol, nebivolol, and digoxin) in the prevention of POAF (RR, 1.28; 95% CI: 0.76-2.16; P = .35) with moderate heterogeneity (I2 = 43%; P = .15). Recent studies suggest that atenolol could be a safe and effective intervention for the prevention of POAF in adult patients undergoing CS."

Clinical • Journal • Retrospective data • Atrial Fibrillation • Cardiovascular

Retraction Note: Renal protective effect of nebivolol in rat models of acute renal injury: role of sodium glucose co-transporter 2. (PubMed, Pharmacol Rep) - No abstract available

Journal • Preclinical • Acute Kidney Injury • Renal Disease

A real-world study on the generic drug of nifedipine controlled-release tablets and the original drug (Bystolic) (ChiCTR) - P=N/A | N=1700 | Not yet recruiting | Sponsor: West China Hospital, Sichuan University; West China Hospital, Sichuan University

New trial • Real-world evidence • Cardiovascular • Hypertension

Nebivolol treatment improves hypertension-induced endothelial cell dysfunction by reducing TGF-β1-dependent senescence and normalizing mitochondrial indices. (PubMed, J Hypertens) - "Nebivolol was the most effective at reducing the factors, associated with HT induced cellular senescence of endothelium, through reducing TGF-β1."

Journal • Cardiovascular • Hypertension • Oncology • ANGPT1 • CCL2 • FGF • HIF1A • IGF1 • TGFB1 • TNFA • TP53BP1

ESONIA - The evaluation of efficacy and safety of Nebivolol in the treatment of arterial hypertension in adolescents. (clinicaltrialsregister.eu) - P2/3 | N=150 | Completed | Sponsor: Medical University Of Warsaw | Recruiting ➔ Completed

Trial completion • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Renal Disease

Therapeutic use of cardioselective beta-blockers for patients with chronic obstructive pulmonary disease: a review of current clinical evidence. (PubMed, Curr Med Res Opin) - "Recent trials evaluating cardioselective β-blockade suggest that cardioselective beta-blockers such as bisoprolol, metoprolol and nebivolol are safe and likely beneficial in those patients that would benefit from their intake due to presence of cardiac comorbid diseases. The aim of this systematic review is to summarise the recent trials and indications for use of cardioselective β-blockers in patients with COPD."

Journal • Review • Cardiovascular • Chronic Obstructive Pulmonary Disease • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Hypertension • Immunology • Pulmonary Disease • Respiratory Diseases

The Beta-Blocker Nebivolol Therapy in Acute Ischemic Stroke: Effects on Nitric Oxide Metabolism (EAN 2026) - No abstract available

Cardiovascular • Ischemic stroke

The Nephroprotective Effects of Nebivolol Against Cyclophosphamide-Induced Toxicity Occur via Antioxidant and Anti-Inflammatory Pathways. (PubMed, J Biochem Mol Toxicol) - "Nebivolol exerts nephroprotective effects via antioxidant and anti-inflammatory pathways, preventing cyclophosphamide-induced renal dysfunction. These beneficial effects suggest nebivolol could help prevent the renal toxicity associated with cyclophosphamide."

Journal • Immunology • Inflammation • Nephrology • Oncology • Renal Disease • MMP9

Discovery of potential AXL inhibitors using virtual screening, molecular docking, molecular dynamics, molecular mechanics, and in vitro validation. (PubMed, Sci Rep) - "In vitro studies with the three lead compounds (STOCK1N-80636, STOCK1N-66436 and Nebivolol) demonstrated significant antiproliferative effects in four different breast cancer cell lines STOCK1N-80636 was being the most potent. In conclusion, these findings have enabled the identification of potential AXL inhibitors through integrated in silico and in vitro results."

Journal • Preclinical • Brain Cancer • Breast Cancer • Glioma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Rifampicin for the treatment of a cardiogenic shock related to mavacamten toxicity: the worse and the best of drug interactions from a case report. (PubMed, Eur Heart J Case Rep) - "She was initiated on mavacamten 5 mg once daily (CYP2C19 genotyping showed no mutation) because of persistent significant obstruction and dyspnoea (NYHA class II) under nebivolol. Although initial tolerance was good with a reassuring transthoracic echocardiography at 4 months, she experienced a severe cardiogenic shock related to mavacamten overdose in the context of esomeprazole initiation (proton pump inhibitor that strongly interacts with the cytochrome CYP2C19 and CYP3A4) for an oesophageal pyrosis by her general practitioner 8 months later...Patient and caregiver information about these potential interactions is highly important. This case also emphasizes that the dosage of mavacamten is now available (and should be used in specific situations) and that mavacamten toxicity can rapidly be overcome by early rifampicin administration, a strong hepatic enzyme inducer."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Gastrointestinal Disorder • Heart Failure • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy • Pulmonary Disease • CYP2C19 • CYP3A4

Association of β-blocker selectivity with survival and immune-related outcomes in melanoma and lung cancer patients treated with immune checkpoint inhibitors. (ASCO 2026) - "Adult patients (≥18 years) with melanoma or lung cancer treated with immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab, atezolizumab, durvalumab, cemiplimab, or avelumab) were identified. Patients were categorized based on exposure to non-selective β-blockers (carvedilol, propranolol, nadolol, labetalol, timolol) or selective β-blockers (metoprolol, atenolol, bisoprolol, nebivolol, acebutolol) within two months before or at ICI initiation... In this real-world, propensity-matched analysis, non-selective β-blocker use was associated with improved early survival and reduced healthcare utilization among melanoma and lung cancer patients treated with ICIs. These findings suggest that non-selective β-blockers represent a low-cost and available adjunct to immunotherapy and warrants prospective validation."

Checkpoint inhibition • Clinical • Lung Cancer • Melanoma • Oncology • Solid Tumor

Model-informed dose optimization of carvedilol and nebivolol in cirrhotic patients: a pilot randomized clinical study. (PubMed, Sci Rep) - "While both drugs controlled blood pressure, carvedilol improved portal hemodynamics more. PBPK-guided dosing addressed pharmacokinetic changes, but pharmacodynamic differences between CP-A and CP-B persisted due to disease progression."

Clinical • Journal • Cardiovascular • Fibrosis • Gastroenterology • Hepatology • Hypertension • Immunology • Liver Cirrhosis • Portal Hypertension • Pulmonary Arterial Hypertension